Cargando…
Aspects spécifiques de la production dans le domaine des vaccins()
The industrial development of vaccine manufacturing expanded during the second half of the 20th century. Vaccines are medicines which target healthy people. The active principles of vaccines arise from live organisms and can be distinguished from standard pharmaceutical compounds by their extreme co...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094674/ https://www.ncbi.nlm.nih.gov/pubmed/19446672 http://dx.doi.org/10.1016/j.pharma.2009.02.008 |
_version_ | 1783510519968169984 |
---|---|
author | Speck, D. |
author_facet | Speck, D. |
author_sort | Speck, D. |
collection | PubMed |
description | The industrial development of vaccine manufacturing expanded during the second half of the 20th century. Vaccines are medicines which target healthy people. The active principles of vaccines arise from live organisms and can be distinguished from standard pharmaceutical compounds by their extreme complexity. The properties of vaccines depend mainly of the manufacturing process and it common to state that “the process makes the product”. The manufacturing is done in confined rooms because of the pathogenic characters of the organisms involved. Raw materials are subjected to rigorous controls to guarantee the integrity of products towards non-conventional agents like prion. The vaccine industry is characterized by the length of the manufacturing cycle. The complexity of the products implies heavy quality controls, which represent 75% of the total duration of the manufacture cycle. As a key element of public health, the vaccine production can be subjected to variations and adaptations, in particular in the context of outbreaks or bioterrorism. The vaccine industry must integrate the regulatory requirements, which are more and more pressing. The spectacular development of the quality assurance and quality control departments these last 15 years testifies to this evolution. |
format | Online Article Text |
id | pubmed-7094674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70946742020-03-25 Aspects spécifiques de la production dans le domaine des vaccins() Speck, D. Ann Pharm Fr Article The industrial development of vaccine manufacturing expanded during the second half of the 20th century. Vaccines are medicines which target healthy people. The active principles of vaccines arise from live organisms and can be distinguished from standard pharmaceutical compounds by their extreme complexity. The properties of vaccines depend mainly of the manufacturing process and it common to state that “the process makes the product”. The manufacturing is done in confined rooms because of the pathogenic characters of the organisms involved. Raw materials are subjected to rigorous controls to guarantee the integrity of products towards non-conventional agents like prion. The vaccine industry is characterized by the length of the manufacturing cycle. The complexity of the products implies heavy quality controls, which represent 75% of the total duration of the manufacture cycle. As a key element of public health, the vaccine production can be subjected to variations and adaptations, in particular in the context of outbreaks or bioterrorism. The vaccine industry must integrate the regulatory requirements, which are more and more pressing. The spectacular development of the quality assurance and quality control departments these last 15 years testifies to this evolution. Elsevier Masson SAS. 2009-05 2009-04-05 /pmc/articles/PMC7094674/ /pubmed/19446672 http://dx.doi.org/10.1016/j.pharma.2009.02.008 Text en Copyright © 2009 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Speck, D. Aspects spécifiques de la production dans le domaine des vaccins() |
title | Aspects spécifiques de la production dans le domaine des vaccins() |
title_full | Aspects spécifiques de la production dans le domaine des vaccins() |
title_fullStr | Aspects spécifiques de la production dans le domaine des vaccins() |
title_full_unstemmed | Aspects spécifiques de la production dans le domaine des vaccins() |
title_short | Aspects spécifiques de la production dans le domaine des vaccins() |
title_sort | aspects spécifiques de la production dans le domaine des vaccins() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094674/ https://www.ncbi.nlm.nih.gov/pubmed/19446672 http://dx.doi.org/10.1016/j.pharma.2009.02.008 |
work_keys_str_mv | AT speckd aspectsspecifiquesdelaproductiondansledomainedesvaccins |